Prevalence and Correlates of Emergency Contraceptive Use in Transitional Albania

Citation for published version (APA):

Document status and date:
Published: 01/07/2019

DOI:
10.1055/s-0043-119085

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at: repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Prevalence and Correlates of Emergency Contraceptive Use in Transitional Albania

Prävalenz und Korrelate des Gebrauchs von Notfallkontrazeptiva in Albanien

Authors
Dajana Roshi1, 2, Salvatore Italia1, Genc Burazeri1, 3, Helmut Brand1

Affiliations
1 Department of International Health, School CAPHRI, Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands
2 National Agency for Drugs and Medical Devices, Tirana, Albania
3 Faculty of Medicine, University of Medicine, Tirana, Albania

Key words
Albania, drug utilization, emergency contraceptive, health policy, levonorgestrel, socioeconomic background

Schlüsselwörter
Albanien, Arzneimittelgebrauch, Notfallkontrazeptiva, Gesundheitspolitik, Levonorgestrel, Sozioökonomischer Status

Bibliography
DOI https://doi.org/10.1055/s-0043-119085
Online-Publikation: 6.11.2017
Gesundheitswesen 2017; 79: e127–e132
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0941-3790

Correspondence
Dajana Roshi, MSc. Pharmacy
Republika e Shqiperise Ministria e Shendetesise Pharmacovigilance Sector
Dibra street no. 359/1
1000, Tirana
Albania
dajana.roshi@yahoo.com

ABSTRACT

Objectives The two emergency contraceptive drugs (“morning-after pill”) ulipristal acetate and levonorgestrel are available without prescription in many European countries. In Albania, ulipristal acetate is not marketed yet and levonorgestrel has still prescription-only status. The objective of this study was to assess the prevalence and socioeconomic correlates of emergency contraceptive (EMC) use, collect sales figures, and gain information on the women’s way of purchasing EMCs in post-communist Albania.

Methods For this cross-sectional study, self-administered questionnaires were made accessible to women in Albania in March 2015 by hard copy or online via social networks. Women were asked about lifetime use and last year’s use of EMCs, and if they purchased EMCs with or without a prescription. Additionally, pharmacies were contacted and asked about EMC sales figures.

Results Of the 205 participating women, 80.5 % knew about the availability and use of EMCs, and 15.1 % reported EMC use during the previous 12 months. The lifetime prevalence of use was 46.8 %. Although having prescription-only status in Albania, 96 % of the women bought EMCs without a physician’s prescription. Knowledge was significantly lower among the lower educated women and among women residing in small cities. Use of EMCs was significantly higher in women with a weaker financial background and, compared with small cities, in those from large or mid-sized cities. The 54 participating pharmacies (3 % of all Albanian pharmacies) reported selling 11 EMCs on average per month. The use of EMCs may be estimated at 0.22 defined daily doses per 1,000 inhabitants per day. Compared to January 2015, EMC sales increased by 17 % in February 2016.

Conclusions Compared to other European countries, the prevalence of EMC use seems to be higher in Albania. Use and knowledge of EMCs depend on socioeconomic characteristics. It is recommended to switch EMCs to non-prescription status in transitional Albania.

ZUSAMMENFASSUNG

Methodik  Für diese Querschnittstudie wurden im März 2015
selbst auszufüllende Fragebögen an Frauen in Albanien verteilt
oder über Internet mittels sozialer Netzwerke zugänglich
gemacht. Die Frauen wurden gefragt, ob sie jemals oder
während der letzten 12 Monate Notfallkontrazeptiva verwendet
hatten, und ob sie das Notfallkontrazeptivum mit oder ohne
Rezept erworben hatten. Zusätzlich wurden auch Apotheken
kontaktiert und gebeten, ihre Verkaufszahlen zu Notfallkon-
trazeptiva zu übermitteln.

Ergebnisse  Von den 205 Teilnehmerinnen waren 80,5 % über
die Möglichkeit der Notfallkontrazeption informiert. 15,1 % hat-
ten ein Notfallkontrazeptivum innerhalb der letzten 12 Monate
verwendet. Die Lebenszeitprävalenz lag bei 46,8 %. Obwohl Not-
fallkontrazeptiva in Albanien verschreibungspflichtig sind, erwar-
ben 96 % der Frauen diese Mittel ohne ärztliche Verordnung.
Frauen mit geringerer Bildung und Frauen aus Kleinstädten
waren signifikant weniger über die Möglichkeit der Notfallkon-
trazeption informiert. Der Gebrauch von Notfallkontrazeptiva
war bei Frauen mit schwächerem finanziellen Hintergrund sig-
nifikant erhöht, ebenso wie bei Frauen aus mittelgroßen Städten
und Großstädten (im Vergleich zu Kleinstädten). Die 54 teilne-
hmenden Apotheken (3 % aller albanischen Apotheken) gaben
an, durchschnittlich 11 Notfallkontrazeptiva pro Monat verkauft
ten zu haben. Der Gebrauch von Notfallkontrazeptiva kann grob mit
0,22 definierten Tagesdosen pro 1000 Einwohner und Tag ge-
schätzt werden. Verglichen mit Januar 2015 wurden im Februar
2016 17 % mehr Notfallkontrazeptiva verkauft.

Schlussfolgerung  Im Vergleich zu anderen europäischen
Ländern scheint der Gebrauch von Notfallkontrazeptiva in Al-
banien höher zu sein. Sowohl Gebrauch von als auch Wissen
über Notfallkontrazeptiva hängen von sozioökonomischen
Faktoren ab. Die Entlassung dieser Arzneimittel aus der Ver-
 verschreibungspflicht ist in Albanien empfehlenswert.

Introduction
The issue of unwanted pregnancies is a relevant public health topic,
as about 41 % of all pregnancies worldwide and 44 % of pregnan-
cies in Europe have been reported by women to be unintended [1].
Especially among young adolescent women aged 15–19 years, the
majority of pregnancies may be unwanted [1], which might lead to
higher abortion rates in this age group. The topics of unwanted
(teen) pregnancies or the use of (emergency) contraceptives are
also linked to socioeconomic factors [2–8]. Unplanned pregnan-
cies are more likely among financially weaker women [2], younger
women [2, 5], or lower educated women [4, 5]. In Finland, a lower
use of emergency contraceptive (EMC) drugs was related to living
in rural areas and to higher paternal education background [9]. A
French study found a higher EMC use among higher educated
women and those living in large cities [10].

An EMC can prevent from unintended pregnancy if taken quick-
ly after unprotected sexual intercourse. Two active pharmaceutical
ingredients are available in Europe for this purpose, levonorg-
estrel (LNG) with a single dose of 1.5 mg and ulipristal acetate
(UPA). To speed up access to EMCs, the European Medicines Agen-
cy recommended switching UPA to non-prescription status in No-
Vember 2014 [11]. As of February 2017, LNG and/or UPA are freely
available in many European countries [12, 13].

Before 1990, contraceptives were generally banned in Albania.
After the breakdown of the communist regime, Albania experi-
enced a major political, social, and economic turmoil. In the past
two decades, tremendous changes in lifestyle have taken place,
which include also the attitudes towards and the use of pharma-
ceutical products. Two LNG-containing EMCs are currently availa-
able in Albania, Norlevo® (registered in January 2005) and Pos-
tinor-2® (registered in March 2012). Both LNG-based EMCs have
still prescription-only status. UPA has been registered in May 2016
as a freely available EMC, but it is not marketed in Albania yet.

Data on EMC use in Albania is rather scarce. In this context, this
study had two objectives:

i) to assess the knowledge about EMCs and the prevalence and
the socioeconomic correlates of EMC use in Albania.

ii) to provide figures for EMC sales and information on the wom-
en’s way of purchasing EMCs.

Material and methods

Study population and data collection
This cross-sectional study was conducted in Albania over a period
of 3 weeks in March 2015. To assess the prevalence of EMC use
(within the last year; and lifetime use) and the women’s socioeco-

nomim background (age, place of residence, education, financial
status), structured self-administered questionnaires were handed
out to female students at 2 universities. Further questions such as
knowledge about the possibility of emergency contraception with
pharmaceuticals, way of purchase (with or without prescription,
bought abroad) or if the women had encountered any problems
when asking for an EMC prescription were also included in the ques-
tionnaire.

Additionally, pharmacies were also invited to provide data using
another questionnaire. They were asked to report prices for EMCs
and monthly sales figures for the 2 registered EMC brands (Nor-
levo®, Postinor-2®) in Albania for the period January 2015 until Febru-
ary 2016, whether they would consider it to be common practice
to sell EMCS without prescription, and if they had cases where
women could not afford to buy an EMC.

In addition to the paper-based questionnaires, identical online
versions were designed for the women and the pharmacies using
google forms (https://www.google.al/forms/about/). The link was
shared in social networks or sent by email to randomly chosen
women and pharmacies. All data were collected anonymously or
 anonymized, if necessary.

Statistical analysis
For the statistical analysis, the SAS software package (SAS Institute
Inc., Cary, NC, USA, version 9.3) was used. Bivariate associations
were tested with Pearson Chi² test or, in case of too small cell values of the contingency tables, with Fisher’s exact test. Odds ratios (ORs) and their 95% confidence intervals (CI) were obtained from a multivariate logistic regression model (significance level: p ≤ 0.05).

The participants were grouped into 3 age classes (16–24 years, 25–34 years, ≥ 35 years). The following education levels were defined according to the participants’ years they attended school:
- Level 1: 10–12 school years (high school education)
- Level 2: 13–15 school years (bachelor education)
- Level 3: 16–17 school years (master education)
- Level 4: ≥ 18 school years (postgraduate studies)

The financial background was defined on the basis of self-perceived ability to meet the daily needs (cannot or can only meet the vital daily needs; can easily meet the daily needs).

The participants’ place of residence was classified in 3 categories (Tirana, mid-sized cities with inhabitants between 50,000–170,000 inhabitants, small cities with 20,000 inhabitants or less).

The study was approved by the Scientific Committee of the National Institute of Public Health in Albania. All participants gave their informed consent after being explained the aim and procedures of the study.

Results

Sample structure and prevalence of knowledge about and use of emergency contraceptives

Overall, 205 women aged 16–60 years from various Albanian regions participated in the survey (89 out of 89 distributed hard copy questionnaires were returned; 116 women submitted the completed questionnaire via Internet). Most of the participants attended school between 16–17 years (n = 135). 10% of the women did some postgraduate studies (≥ 18 school years), while 4% went to school for 10–12 years only. Exactly 97 women said they would not be able to meet their daily needs (n = 3) or could only meet their vital daily needs (n = 94), whereas 108 women reported that they would easily be able to meet their daily needs. The majority of the women (n = 151) resided in Tirana, Albania’s largest city (with about 500,000 inhabitants). A further 22 women lived in mid-sized cities (Durres, Elbasan, Fier, Korça, Vlora). The remaining 12 participants came from 6 smaller or rather rural cities (Kashar, Kruje, Lezha, Perrenjas, Pogradec, Sarande,) with a population between 6,000–20,000 inhabitants (missing values n = 20). The exact sample structure is displayed in Table 1.

Overall, 80.5% (95% CI: 74.8–86.2%) of the women knew about the possibility of avoiding unintended pregnancy by using an EMC. Exactly 15.1% (95% CI: 10.0–20.3%) of the women reported having used EMCs at least once within the previous 12 months, and 46.8% (95% CI: 39.8–53.9%) took an EMC at least once in their lifetime. However, knowledge about and use of EMCs were not homogeneous across the socioeconomic strata.

Knowledge was highest among those aged 25–34 years. Also, a significant difference was visible between the highest (85%) and lowest (62.5%) education level. Women from Tirana (83.4%) were much better informed on the issue of EMCs compared with women living in mid-sized (68.2%) or smaller cities (58.3%).

The figures for the 1-year prevalence of use (18.6%) and for lifetime use (53.6%) were higher among women with problems to meet their daily needs, compared with women who perceived their financial situation as unproblematic (1-year prevalence = 12.0%; lifetime use = 40.7%). Compared with urban areas, only few women living in small cities with 20,000 inhabitants or less used EMCs (no woman reported use within the last year, 8.3% reported lifetime use).

Of the 96 women who used EMCs, exactly 92 (95.8%) said they bought it without a physician’s prescription, although LNG-containing EMCs have still a prescription-only status in Albania. Some 13 women bought EMCs also or exclusively outside Albania (7 in Italy, 2 in Germany, 1 respectively in Macedonia, Greece, America, and Norway). With regard to affordability, 8 participants stated that they had hesitated to buy an EMC because of the high price, but all 8 reported having nevertheless finally bought the EMC.

A total of 5 women experienced some kind of problem with the physician in relation to the prescription of an EMC. For instance, two complained not being informed about side effects sufficiently or correctly, one got necessary information from the pharmacist instead of the physician, and one woman mentioned the physician was not available when she needed him.

Correlates of emergency contraceptive use

A logistic regression model (Table 2) with 4 independent variables (simultaneously-adjusted model without interaction terms) revealed that a strong “predictor” of lifetime use of EMCs was a weaker financial background. Women who had difficulties in meeting their daily needs used almost twice as much EMCs (significant at p = 0.0382) compared with women from a stable financial background (OR = 0.53; 95% CI: 0.29–0.97). Also, the place of residence showed an association with EMC use, as, compared with Tirana, women living in mid-sized cities (OR = 0.65; 95% CI: 0.24–1.74) and especially those living in small cities (OR = 0.11; 95% CI: 0.01–0.91) and significantly at p = 0.0409 used much fewer EMCs.

No logistic regression model for the 1-year prevalence of use and the knowledge about EMCs is presented at this place, as for both outcomes, the likelihood ratios of the SAS model fit statistics did not satisfy the criterion of p ≤ 0.05.

Sales figures

54 Albanian pharmacies from 8 cities (Berat, Elbasan, Fier, Gjirokaster, Korça, Kukes, Pogradec, Tirana) reported sales figures for the 2 currently available LNG-containing EMC brands (Norlevo®, Postinor-2®) in Albania for the period between January 2015 and February 2016 (one pharmacy submitted the data via Internet). Compared with January 2015, the number of sold packages slightly increased by 15% for Postinor-2® and 18% for Norlevo®, respectively (Fig. 1). In total, the 54 participating pharmacies sold 8,404 EMCs within 14 months (Fig. 1). The price for Norlevo® ranged between 582 and 660 lek (€4.31–4.89). The price range for Postinor-2® was 530–649 lek, which corresponds to €3.93–4.81 (exchange rate as of February 2017: 1 euro = 135 lek; for comparison: mean monthly gross income for employees at state authorities = 22,000 lek, about €163 [14]).

16 out of 54 pharmacies stated having had cases, where potential customers finally did not buy the EMC because it was not afford-
In sum, these 16 pharmacies estimated the number of respective cases at about 35 for a period of one month. Exactly 48 (88.9%) pharmacies reported they thought it might be quite a common practice to sell EMCs also without a physician’s prescription.

### Discussion

The results of this study imply that the use of EMCs might be higher in post-communist Albania compared with other European countries. A 2004 study from France [10] found a lifetime prevalence of 31.7% (compared to 46.8% in Albania). In the United Kingdom [15], 7.3% of the women aged 16–49 years (data published in 2005) used EMCs at least once during the last year (compared with 15.1% in Albania). In a Finnish study conducted in 1996, 15.1% of 17-year-old girls reported to have used EMCs at least once during lifetime [16], which may be somewhat higher today, since in Finland, EMCs were switched to non-prescription status in 2002.

The sales figures presented in this study provided by 54 Albanian pharmacies (about 3% of the 1,800 pharmacies currently operating in Albania) may be extrapolated to a total yearly consumption of about 240,000 defined daily doses (DDDs) in Albania, corresponding to 0.22 DDDs per 1,000 inhabitants per day. This would be much higher than, for instance, in Denmark, where the consumption is on an almost stable level at 0.049 DDDs per 1,000 inhabitants per day since 2008. A lower consumption has also been reported for Estonia (stable for the period 2010–2014 at 0.06-0.07 DDDs per 1,000 inhabitants per day) and Montenegro (stable for the period 2012–2014 at 0.04 DDDs per 1,000 inhabitants per day). In Switzerland, the consumption of EMCs increased strongly after the switch to non-prescription status in 2002 to about 0.031 DDDs per 1,000 inhabitants per day in 2008, which is nevertheless still lower compared with Albania. In Germany, where EMCs are freely available since 2015, the consumption of EMCs seems to have reached a stable level of currently about 0.025 DDDs per 1,000 in-

### Table 1 Sample structure and prevalence of knowledge about and use of emergency contraceptives.

<table>
<thead>
<tr>
<th>n (%)</th>
<th>Knowledge about EMCs</th>
<th>Use within the last year</th>
<th>Use during lifetime</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cohort 205 (100)</td>
<td>80.5</td>
<td>15.1</td>
<td>46.8</td>
</tr>
<tr>
<td>Age class</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16–24 years 102 (49.8)</td>
<td>75.5</td>
<td>11.8</td>
<td>38.2</td>
</tr>
<tr>
<td>25–34 years 83 (40.5)</td>
<td>89.2</td>
<td>0.0303 a</td>
<td>16.9</td>
</tr>
<tr>
<td>35 years or older 20 (9.8)</td>
<td>70.0</td>
<td></td>
<td>25.0</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10–12 school years 8 (3.9)</td>
<td>62.5</td>
<td>12.5</td>
<td>50.0</td>
</tr>
<tr>
<td>13–15 school years 42 (20.5)</td>
<td>66.7</td>
<td>0.0275 b</td>
<td>14.3</td>
</tr>
<tr>
<td>16–17 school years 135 (65.9)</td>
<td>85.2</td>
<td>16.3</td>
<td>54.8</td>
</tr>
<tr>
<td>18 school years or more 20 (9.8)</td>
<td>85.0</td>
<td>10.0</td>
<td>40.0</td>
</tr>
<tr>
<td>Financial situation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannot or can only meet vital daily needs 97 (47.3)</td>
<td>78.4</td>
<td>0.4643 a</td>
<td>18.6</td>
</tr>
<tr>
<td>Can easily meet daily needs 108 (52.7)</td>
<td>82.4</td>
<td>12.0</td>
<td>40.7</td>
</tr>
<tr>
<td>Place of residence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tirana 151 (73.7)</td>
<td>83.4</td>
<td>16.6</td>
<td>49.0</td>
</tr>
<tr>
<td>Mid-sized cities 22 (10.7)</td>
<td>68.2</td>
<td>0.0360 b</td>
<td>13.6</td>
</tr>
<tr>
<td>Small cities 12 (5.9)</td>
<td>58.3</td>
<td>0.0</td>
<td>8.3</td>
</tr>
</tbody>
</table>

EMC, emergency contraceptive; a p-value derived from Pearson Chi² test; b p-value derived from Fisher’s exact test; Due to missing values, the strata may not add up to the total number of participants.

### Table 2 Correlates of lifetime use of emergency contraceptives.

<table>
<thead>
<tr>
<th>n (%)</th>
<th>Lifetime use of EMCs (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age class</td>
<td></td>
</tr>
<tr>
<td>16–24 years 102 (49.8)</td>
<td>Reference</td>
</tr>
<tr>
<td>25–34 years 83 (40.5)</td>
<td>1.79 (0.88–3.63)</td>
</tr>
<tr>
<td>35 years or older 20 (9.8)</td>
<td>1.35 (0.46–3.97)</td>
</tr>
<tr>
<td>Education</td>
<td></td>
</tr>
<tr>
<td>10–12 school years 8 (3.9)</td>
<td>Reference</td>
</tr>
<tr>
<td>13–15 school years 42 (20.5)</td>
<td>0.42 (0.08–2.32)</td>
</tr>
<tr>
<td>16–17 school years 135 (65.9)</td>
<td>1.20 (0.25–5.68)</td>
</tr>
<tr>
<td>18 school years or more 20 (9.8)</td>
<td>0.48 (0.08–2.87)</td>
</tr>
<tr>
<td>Financial situation</td>
<td></td>
</tr>
<tr>
<td>Cannot or can only meet vital daily needs 97 (47.3)</td>
<td>Reference</td>
</tr>
<tr>
<td>Can easily meet daily needs 108 (52.7)</td>
<td>0.53 * (0.29–0.97)</td>
</tr>
<tr>
<td>Place of residence</td>
<td></td>
</tr>
<tr>
<td>Tirana 151 (73.7)</td>
<td>Reference</td>
</tr>
<tr>
<td>Mid-sized cities 22 (10.7)</td>
<td>0.65 (0.24–1.74)</td>
</tr>
<tr>
<td>Small cities 12 (5.9)</td>
<td>0.11 * (0.01–0.91)</td>
</tr>
</tbody>
</table>

CI, confidence interval; EMC, emergency contraceptive; * significant at p ≤ 0.05; Due to missing values, the strata may not add up to the total number of participants.
habitants per day [13, 17]. However, the estimation for Albania is rough and needs to be investigated on a larger data basis.

The use of EMCs is known to be predicted by socioeconomic factors. An Australian study [18] as well as an American one [19] showed that being not married increases the probability to use an EMC. A higher education was also linked to a higher use of EMCs in America [19]. In this Albanian study, EMC use was not associated with educational background. However, a higher use of EMCs among Albanian women correlated significantly with weaker financial background and living in an urban environment. The impact of financial background could possibly be explained by the fact that poor women may be able less to afford having children. A further explanation could be that poor women do not take normal contraceptive pills because of the price (which cost around 6–10 euros per cycle), but prefer to take a (cheaper) single dose of an EMC pill in case of need. According to the European consortium for emergency contraception, only 11.7% of Albanian women use modern contraceptive methods, compared with e.g., 67–76% in Austria, Hungary, Denmark, France, or Germany [12]. Also, the perception of having fewer side effects by using a single-dose EMC instead of regularly using normal hormonal contraception could explain the high Albanian prevalence rates of EMC use. In this context it should be mentioned, that EMCs should, however, not be used as an ongoing method of contraception.

EMCs are not reimbursed in Albania and have therefore to be paid out of pocket. The hypothesis, that financial background could play a role is also strengthened by the fact that 4% of the surveyed women said they had hesitated to buy an EMC. Additionally, 30% of the participating pharmacies reported to recall a total of about 35 cases within a period of about 15 cases per month, where women could not afford to buy the EMC needed because of the high price.

With concern to the knowledge about EMCs, there seems to be a need to improve health literacy especially in rural Albania. This could be done, e.g. with TV commercials or by sending small groups of health professionals by state authorities, who could organize respective meetings with women living in rural areas.

This study has strengths and limitations. To our knowledge, this is the very first study presenting figures on the relevant topic of EMC use in Albania. Furthermore, it provides an updated view on EMC sales figures over a period of 14 months provided by a relatively large number of pharmacies. However, one important limitation is the comparatively small number of participating women in this study. Also, the composition of the study cohort is not exactly representative for Albania, as e.g. the lower-educated strata and those living in more rural areas are underrepresented in this study. Moreover, the study included mainly students from urban areas, who may have a more stable financial background, compared with women residing in a rural environment. Furthermore, with respect to e.g. educational background or place of residence, the strata differ in size considerably, which may have reduced the significance of the results. In sum, the representativeness of the sample is limited and therefore, the findings should be interpreted with some reticence. For the future, more data from e.g. population based studies would be helpful.

Conclusions

It may finally be concluded that EMC-related health literacy needs to be improved in Albania, especially in rural areas. Furthermore, EMCs should be switched to free availability. By doing this, dispensing over the counter in pharmacies (which evidently is common practice in Albania) would be put on a legal basis and potential drug tourism (although unlikely) would be minimized.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare that they have no competing interests.
References


